Table 1.
The reported studies indicate drug-induced liver injury in COVID-19 patients.
| Study Type | Enrolled Patients | Medication Type | Dose Concentration (mg) | Duration | Drug-Induced Liver Injury | Outcomes | References |
|---|---|---|---|---|---|---|---|
| Case Study | 4 | Remdesivir, Hydroxychloroquine | 10 | Daily | Elevated AST and ALT (5–8 times) | Liver cirrhosis, cardiac failure, and organ dysfunction | [44] |
| Randomized design | 158 | Lopinavir, Remdesivir, Corticosteroids | 100 | Daily | AST/ALT (5 times folds) | Adverse effects (Liver dysfunction and circulatory failure) were observed in 102 patients | [45] |
| Case Study | One patient susceptible to medication | Chloroquine, Methylprednisolone, Tocilizumab | 500 | Daily | Transaminase elevated (10 times folds) | Autoimmune liver disease, cytokine release syndrome | [42] |
| Cross-sectional | 417 | Ribavirin, Ritonavir | Undetected thought the study | Throughout treatment | AST/ALT (3 times folds) | Hepatocellular carcinoma, NAFLD | [4] |
| Retrospective | 179 | Tocilizumab | 800 | 24 h | Transaminase sharply after dosage | Liver cirrhosis | [46] |
| Case Study | One patient susceptible to study | Favipiravir | 6000 | Daily | Transaminase was significantly elevated | Cholestasis liver disease | [47] |
| Case Study | 5 | Remdesivir | 200 | Daily | ALT was significantly elevated | Advanced liver disease and renal failure | [48] |